Product Center
Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-08-15
- Views:
(Summary description)Caring for life, safeguarding health. Ab&B Bio will continue to pursue its mission through concrete actions—ensuring that China has access to globally innovative vaccines and that the world can benefit from China's high-quality vaccines!
Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations!
(Summary description)Caring for life, safeguarding health. Ab&B Bio will continue to pursue its mission through concrete actions—ensuring that China has access to globally innovative vaccines and that the world can benefit from China's high-quality vaccines!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-08-15 13:58
- Views:
National Premiere
On August 14,2026, Ab&B Bio-Tech CO.,LTD.JS (hereinafter referred to as "Ab&B Bio") officially launched its influenza virus subunit vaccine, which was subsequently distributed nationwide by all provincial Centers for Disease Control and Prevention (CDC) during the 2026–2027 influenza season.
This is China's first and only subunit influenza vaccine suitable for administration at full dose to all individuals aged 6 months and older, marking a milestone breakthrough in the country's high-end influenza vaccine sector and providing a stronger scientific safeguard for the upcoming influenza season.
Leadership Address
Jiang Peng, Deputy Director of the Taizhou Pharmaceutical High-Tech Zone Management Committee, Secretary of the Party Working Committee of the Pharmaceutical Industrial Park, and Director of the Management Office, stated in his address: "This year marks the 30th anniversary of the establishment of Taizhou City (a prefecture-level city) and the 20th anniversary of the development of the China Pharmaceutical City. Ab&B Bio has aligned its growth with that of the industrial park, serving as a typical example of local vaccine manufacturers achieving innovative breakthroughs. The newly listed HRK-X® 3 is the only trivalent influenza virus subunit vaccine in China designed for all age groups aged 6 months and above, filling a gap in the market and representing a triple breakthrough in technology, quality, and safety, there byestablishing a robust defense against influenza across the population. Standing at this new starting point for building a 100-billion-yuan industrial park under the 15th Five-Year Plan, the industrial park will continue to optimize its business environment, strengthen resource support, and provide comprehensive assistance to Ab&B Bio in increasing its R&D investment, expanding its national market presence, and accelerating its global vaccine deployment. We sincerely hope that Zhonghui will use this listing as a new starting point to uphold its commitment to quality standards, steadily advance toward becoming a leading player in China's human-use vaccine industry, safeguard public health with more high-quality domestic vaccines, and contribute to the high-quality development of Taizhou's biomedical industry!"
An Youcai, Chairman and General Manager of Ab&B Bio, stated: "On the occasion of celebrating the 30th anniversary of the establishment of Taizhou City and the 20th anniversary of the founding of China Pharmaceutical City, the official launch of HRK-X® 3 represents our sincere tribute to this fertile ground for entrepreneurship. In response to the evolving global influenza virus landscape, our team has responded with agility and made scientifically informed decisions, achieving a seamless transition from a quadrivalent to a trivalent vaccine formulation – thereby forging a highly capable team capable of delivering outstanding results. Today, through our all-population, full-dose, high-purity subunit manufacturing process, we once again stand as the 'only' provider in China. This not only demonstrates our robust technological capabilities but also serves as a silent fulfillment of our commitment to 'Leading Quality.' Moving forward, Ab&B Bio will leverage its 'AI-Driven R&D + Intelligent Manufacturing + Precision Marketing' ecosystem to build a dual-driven product portfolio encompassing both prevention and treatment solutions, continuously deliver innovative breakthroughs, deepen our presence in the domestic market, boldly expand into international markets, and establish a new paradigm of synergistic growth both domestically and globally. We remain steadfastly committed to achieving the company's' Three-Five' strategic objectives and contribute to advancing public health initiatives."
About "HRK-X® 3"
Influenza virus subunit vaccine (HRK-X® 3), as a next-generation subunit influenza vaccine, is formulated solely from the influenza virus surface antigens hemagglutinin (HA) and neuraminidase (NA), while excluding all other internal viral protein components. This approach significantly enhances the purity of the vaccine's effective antigens. Compared to traditional vaccines, Huierkangxin 3 not only elicits a precise immune response but also markedly reduces the incidence of adverse reactions, achieving a dual benefit of both high immunogenicity and safety.
The official launch of HRK-X® 3 will provide society with a more advanced, safer, and more effective influenza vaccination option, reduce vaccination hesitancy, further increase influenza vaccination rates, and contribute to the prevention and control of influenza in China!
About Ab&B Bio
Ab&B Bio-Tech CO.,LTD.JS is dedicated to the research, development, manufacturing, and commercialization of innovative vaccines as well as traditional vaccines developed using novel technological approaches. Aligning itself with international standards and committing to independent innovation-driven R&D, the company leverages the strengths of its six major technology platforms. After a decade of growth, it now operates 13 product pipelines, has successfully launched two products on the market, secured 10 clinical trial approvals for new drugs (including seven Class I new drug clinical trial approvals), and obtained three dual application and approval approvals across both China and the United States; additionally, multiple projects are progressing smoothly toward clinical trials and New Drug Application (NDA) submissions.
Looking ahead, Ab&B Bio will continue to uphold its philosophy of "innovation-driven growth and quality leadership," leveraging its integrated three-pillar development framework—comprising AI-powered R&D, smart manufacturing, and precision marketing—to dedicate itself to providing the public with high-quality vaccine products that offer enhanced safety and more comprehensive protection.
Caring for life, safeguarding health. Ab&B Bio will continue to pursue its mission through concrete actions—ensuring that China has access to globally innovative vaccines and that the world can benefit from China's high-quality vaccines!
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groupsInfluenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
